Eli Lilly has acquired worldwide rights to Locemia Solution's intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder glucagon formulation is delivered by a single-use intranasal puffer. No financial terms were disclosed. Lilly Diabetes President Enrique … [Read more...] about Lilly acquires Locemia’s intranasal glucagon powder
News
OptiNose raises up to $30 million for development of intranasal fluticasone
OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products. The company had announced completion of its previous round of financing in August 2014. According to the company, Phase 3 development of … [Read more...] about OptiNose raises up to $30 million for development of intranasal fluticasone
InCarda gets patents for inhaled cardiovascular therapies
InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company's inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No. 8,974,828, issued in March 2015 and titled, “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary … [Read more...] about InCarda gets patents for inhaled cardiovascular therapies
3M DDS partners with Impel NeuroPharma on intranasal delivery technology for CNS drugs
3M Drug Delivery Systems and Impel NeuroPharma have announced that the two companies will collaborate on development and commercialization of Impel’s Precision Olfactory Delivery (POD) platform for intranasal delivery of drugs to the central nervous system. No financial terms were disclosed. Impel CEO Michael Hite commented, “We are pleased to have 3M join our … [Read more...] about 3M DDS partners with Impel NeuroPharma on intranasal delivery technology for CNS drugs
Serendex announces positive topline data from Phase 1 study of Molgradex
Serendex Pharmaceuticals has announced that data from a Phase 1 randomized, double blind, placebo controlled single ascending dose/multiple ascending dose trial showed that Molgradex inhaled GM-CSF (molgramostim) was well tolerated at all dose levels. No serious or severe events were reported, and similar numbers of subjects in both the active and control groups … [Read more...] about Serendex announces positive topline data from Phase 1 study of Molgradex
Phase 2 data show effectiveness of Invion’s inhaled nadolol for smoking cessation
A Phase 2 study of Invion's INV102 inhaled nadolol showed that smokers using the therapy were much more likely to stop smoking or significantly reduce the number of cigarettes they smoked than those using a placebo, the company said. The randomized, double blinded, placebo controlled study also showed a significant reduction in biomarkers for the beta arrestin … [Read more...] about Phase 2 data show effectiveness of Invion’s inhaled nadolol for smoking cessation
Celdara Medical and Pulmatrix get grant for inhaled biologic for idiopathic pulmonary fibrosis
Celdara Medical and Pulmatrix have been awarded a 3-year $1.7 million Fast Track Small Business Innovation Research grant from the National Heart Lung and Blood Institute (NHLBI) for development of an inhaled therapy for the treatment of idiopathic pulmonary fibrosis, the companies said. A dry powder formulation of CM-YJH01, a biologic, will be developed using … [Read more...] about Celdara Medical and Pulmatrix get grant for inhaled biologic for idiopathic pulmonary fibrosis
Alexza Pharmaceuticals announces two promotions
Alexza Pharmaceuticals has promoted Catherine McAuliffe to VP, Operations and Stacy Palermini to VP, Finance, the company said. McAuliffe most recently served as Executive Director, Operations; the position of VP, Operations is newly created. Palermini was previously Executive Director, Finance. Alexza is developing several products using its Staccato inhalation … [Read more...] about Alexza Pharmaceuticals announces two promotions
GSK exercises option to develop inhaled drugs based on Liquidia’s PRINT technology
GlaxoSmithKline has exercised an option for an exclusive license to develop inhaled therapies using Liquidia Techonologies' PRINT particle engineering technology, Liquidia said. The option was included in a collaboration deal the two companies signed in 2012. Liquidia also said that it has retained the right to develop an inhaled therapy independently. Upon … [Read more...] about GSK exercises option to develop inhaled drugs based on Liquidia’s PRINT technology
Verona reports positive data from SAD/MAD trial of RPL554 for COPD
Verona Pharma has announce that data from the third part of single ascending dose (SAD)/multiple ascending dose (MAD) trial of nebulized RPL554 in COPD patients show that the formulation was well tolerated at all doses with no serious adverse events and that patients using RPL554 experienced "pronounced improvement in lung function." Verona reported results from … [Read more...] about Verona reports positive data from SAD/MAD trial of RPL554 for COPD